[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trimethoxybenzoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: [2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trimethoxybenzoate
• 化学式: C₂₅H₂₄O₁₀
• 分子量: 484.5
• InChiKey: YWLGYHHJYFPEJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  144
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• ANTIFOLATE COMPOUNDS FOR THE TREATMENT OF MELANOMA
  申请人：Universidad de Murcia

  公开号：EP2231151B1

  公开（公告）日：2013-08-28
• COMBINATIONS (CATECHINS AND METHOTREXATE) FOR USE IN THE TREATMENT OF MELANOMAS
  申请人：UNIVERSIDAD DE MURCIA

  公开号：US20150231109A1

  公开（公告）日：2015-08-20

  The invention provides a method of treatment of melanoma comprising administering a tyrosinase expression enhancer, such as MTX, and a tyrosinase-activated prodrug, such as TMECG or TMCG, to an individual in need thereof. Also provided is a method of treating melanoma comprising administering a tyrosinase-activated prodrug and a compound for differentiating a stem-like tumor cell into a matured cell that is a tyrosinase producer to an individual in need thereof. Further provided is a method of treatment of melanoma comprising administering a tyrosinase expression enhancer and a tyrosinase-activated prodrug to an individual in need thereof, wherein the individual has a melanoma in which one or more of BRAF, NRAS, p53, GNAQ, EGFR, PDGFR, RAC or c-kit carries a mutation.
• TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH RXR ANTAGONISTS
  申请人：VIB VZW

  公开号：US20210008047A1

  公开（公告）日：2021-01-14

  The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of retinoid X receptor antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of retinoid X receptor antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.
• TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH CD36 ANTAGONISTS
  申请人：VIB VZW

  公开号：US20210008070A1

  公开（公告）日：2021-01-14

  The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of CD36 antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of CD36 antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.
• TUMOR MINIMAL RESIDUAL DISEASE STRATIFICATION
  申请人：VIB VZW

  公开号：US20210010089A1

  公开（公告）日：2021-01-14

  The invention relates to the field of tumor disease stratification, in particular melanoma disease stratification. In particular it relates to the methods for tumor analysis, such as for determining tumor cell heterogeneity during treatment. These methods are helpful in selecting or optimizing tumor therapy, or in predicting responses to tumor therapy. The invention further relates to methods for screening for cytotoxic or cytostatic compounds targeting one or more of the heterogeneous tumor cell populations occurring such as during therapy, such as during the minimal residual disease phase.